DXA assessment and fracture prevention in hormone positive breast cancer patients after treatment initiation with aromatase inhibitors: A registry-based cohort study

Development and efficacy of a computerized decision support system for osteoporosis management in the community

(2020) Inbal Goldshtein et al.   Archives of Osteoporosis

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline

(2019) Charles L. Shapiro et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteoporosis management in patients with breast cancer: EMAS position statement

(2017) Florence A. Trémollieres et al.   MATURITAS

The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom

(2015) Nina Schimdt et al.   BREAST CANCER RESEARCH AND TREATMENT

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture?

(2014) W. D. Leslie et al.   OSTEOPOROSIS INTERNATIONAL

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL